Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
7.24 AUD | +0.28% | +3.43% | +17.72% |
Feb. 26 | Mayne Pharma Group Swings to Loss in Fiscal H1 Despite Revenue Growth; Shares Jump 15% | MT |
Feb. 25 | Transcript : Mayne Pharma Group Limited, H1 2024 Earnings Call, Feb 26, 2024 |
Business Summary
Number of employees: 967
Sales per Business
AUD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
International
35.2
%
| 54 | 12.8 % | 65 | 35.2 % | +19.01% |
Branded Products Division
33.7
%
| 11 | 2.5 % | 62 | 33.7 % | +485.69% |
Portfolio Products Division
31.0
%
| 269 | 63.3 % | 57 | 31.0 % | -78.82% |
Sales per region
AUD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
67.8
%
| 371 | 87.3 % | 124 | 67.8 % | -66.44% |
Australia and New Zealand
22.4
%
| 34 | 7.9 % | 41 | 22.4 % | +22.24% |
Canada
5.4
%
| 9 | 2.1 % | 10 | 5.4 % | +9.62% |
Asia
2.4
%
| 5 | 1.1 % | 4 | 2.4 % | -9.86% |
Europe and Other
2.0
%
| 6 | 1.5 % | 4 | 2.0 % | -42.36% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Shawn O'Brien
CEO | Chief Executive Officer | - | 22-09-30 |
Aaron Gray
DFI | Director of Finance/CFO | - | 22-08-28 |
Keith Moore
CTO | Chief Tech/Sci/R&D Officer | - | 14-12-31 |
Gerard G. Nahum
CTO | Chief Tech/Sci/R&D Officer | - | - |
Frank Casty
CTO | Chief Tech/Sci/R&D Officer | - | - |
Craig Haskins
IRC | Investor Relations Contact | - | - |
Erinn Nathaniel
HRO | Human Resources Officer | - | - |
Kimberly Parker
LAW | General Counsel | - | - |
Richard Moldin
PRN | Corporate Officer/Principal | - | - |
Laura Loftus
PRN | Corporate Officer/Principal | - | 20-03-25 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Frank Condella
CHM | Chairman | 70 | 18-05-29 |
Patrick Blake
BRD | Director/Board Member | 59 | 18-06-27 |
Shawn O'Brien
CEO | Chief Executive Officer | - | 22-09-30 |
Director/Board Member | 58 | 22-01-31 | |
Bruce Robinson
BRD | Director/Board Member | 67 | 14-08-25 |
Anne Lockwood
BRD | Director/Board Member | - | Nov. 29 |
Ann Custin
BRD | Director/Board Member | 64 | 22-03-22 |
David Petrie
BRD | Director/Board Member | - | 22-08-31 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 81,245,827 | 57,414,136 ( 70.67 %) | 0 | 70.67 % |
Company contact information
Mayne Pharma Group Ltd.
1538 Main North Road Salisbury South
5106, Salisbury
+61 8 8209 2666
http://www.maynepharma.comSector
Sales per Business
Sales per region
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+17.72% | 382M | |
+28.67% | 46.19B | |
+18.57% | 22.88B | |
+20.11% | 14.18B | |
+0.55% | 12.63B | |
+46.16% | 12.07B | |
-1.55% | 7.85B | |
-0.05% | 6.79B | |
-8.87% | 5.73B | |
+7.80% | 5.14B |
- Stock
- Equities
- Stock Mayne Pharma Group Limited - Australian S.E.
- Company Mayne Pharma Group Limited